{"id":"W4396515165","doi":"10.1182/bloodadvances.2024012646","title":"Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Gateway for Cancer Research; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Filgrastim; Term (time); Peripheral blood; Stem cell; Peripheral Blood Stem Cells; Medicine; Immunology; Internal medicine; Granulocyte colony-stimulating factor; Hematopoietic stem cell transplantation; Biology; Transplantation; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001230809,0.0002152008,0.0004249972,0.000249099,0.0002948056,0.0006415579,0.0002270609,0.000287418,0.0009807537],"category_scores_gemma":[0.001719928,0.00009303151,0.0005655637,0.0003988154,0.0002235711,0.0003962107,0.000470692,0.000625111,0.0001815531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004858194,"about_ca_system_score_gemma":0.0003676789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004791869,"about_ca_topic_score_gemma":0.0006046863,"domain_scores_codex":[0.999514,0.0001369651,0.00007042995,0.00008078747,0.0001008361,0.00009707503],"domain_scores_gemma":[0.9981596,0.0002833846,0.0008675778,0.0001033376,0.0001534273,0.0004328019],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01044522,0.001227505,0.9561675,0.0001971578,0.0009697134,0.0005048746,0.0001970974,0.0002934686,0.001935985,0.0001144916,0.000581595,0.02736546],"study_design_scores_gemma":[0.0002863478,0.008274542,0.9869282,0.00008641335,0.0006165794,0.0009861297,0.000224346,0.0002910077,0.001074206,0.000111549,0.001104117,0.00001653973],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9976241,0.001835866,0.00007752309,0.00002486031,0.00001188028,0.00001253606,0.0001879995,0.000001576187,0.000223563],"genre_scores_gemma":[0.9989157,0.0003829169,0.0000297881,0.00003949049,0.0000197604,0.00001412131,0.0004494577,7.201659e-7,0.0001480428],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001230809,"threshold_uncertainty_score":0.006509185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01205772023276805,"score_gpt":0.2696585224523246,"score_spread":0.2576008022195565,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}